CYTH News and Press, Cyclo Therapeutics Inc. From 03/18/24

Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the ...

Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments Increased ownership in Day Three Labs to a majority interest of 79% NEWARK, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, I...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...

2023-12-28 10:00:05 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming Healthcare and utilities could perform better in 2024 - analyst Arcus, Bristol-Myers, and R1 RCM are Citi’s top stocks in healthcare For further details see:...

2023-12-28 08:51:19 ET Bluejay Diagnostics ( BJDX ) -36% on pricing of $3.5 million stock offering . Cytosorbents CTSO -29% as blood purification system fails key trial . First Wave BioPharma ( FWBI ) -17% . NKGen Biotech ( NKGN ) -12% . ...

Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo ...

Ongoing pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) FDA feedback provides direction for the comparative interim analysis With aligned strategy, interim analysis d...

NEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023. “During fiscal 2024, we will continue to focus on advancing our existing portfolio and ...

2023-11-22 10:00:14 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...